Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease - PubMed (original) (raw)
Clinical Trial
. 2001 Nov 29;345(22):1583-92.
doi: 10.1056/NEJMoa011090.
X Q Zhao, A Chait, L D Fisher, M C Cheung, J S Morse, A A Dowdy, E K Marino, E L Bolson, P Alaupovic, J Frohlich, J J Albers
Affiliations
- PMID: 11757504
- DOI: 10.1056/NEJMoa011090
Free article
Clinical Trial
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
B G Brown et al. N Engl J Med. 2001.
Free article
Abstract
Background: Both lipid-modifying therapy and antioxidant vitamins are thought to have benefit in patients with coronary disease. We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary disease and low plasma levels of HDL.
Methods: In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos. The end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization).
Results: The mean levels of LDL and HDL cholesterol were unaltered in the antioxidant group and the placebo group; these levels changed substantially (by -42 percent and +26 percent, respectively) in the simvastatin-niacin group. The protective increase in HDL2 with simvastatin plus niacin was attenuated by concurrent therapy with antioxidants. The average stenosis progressed by 3.9 percent with placebos, 1.8 percent with antioxidants (P=0.16 for the comparison with the placebo group), and 0.7 percent with simvastatin-niacin plus antioxidants (P=0.004) and regressed by 0.4 percent with simvastatin-niacin alone (P<0.001). The frequency of the clinical end point was 24 percent with placebos; 3 percent with simvastatin-niacin alone; 21 percent in the antioxidant-therapy group; and 14 percent in the simvastatin-niacin-plus-antioxidants group.
Conclusions: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned.
Comment in
- Antioxidant versus lipid-altering therapy--some answers, more questions.
Freedman JE. Freedman JE. N Engl J Med. 2001 Nov 29;345(22):1636-7. doi: 10.1056/NEJM200111293452210. N Engl J Med. 2001. PMID: 11757512 No abstract available. - Antioxidant vitamins and coronary disease.
Biondi-Zoccai GG, Abbate A, Agostoni P. Biondi-Zoccai GG, et al. N Engl J Med. 2002 Apr 4;346(14):1092-3. doi: 10.1056/NEJM200204043461415. N Engl J Med. 2002. PMID: 11932481 No abstract available. - Coronary artery disease. Prevention with statin and niacin.
Lepor NE. Lepor NE. Rev Cardiovasc Med. 2002 Fall;3(4):205-6. Rev Cardiovasc Med. 2002. PMID: 12556756 No abstract available.
Summary for patients in
- Simvastatin and niacin.
Wilson PW. Wilson PW. Curr Cardiol Rep. 2002 Nov;4(6):486. Curr Cardiol Rep. 2002. PMID: 12379170 No abstract available.
Similar articles
- Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. AIM-HIGH Investigators, et al. N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15. N Engl J Med. 2011. PMID: 22085343 Clinical Trial. - Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.
Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Cheung MC, et al. Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1320-6. doi: 10.1161/hq0801.095151. Arterioscler Thromb Vasc Biol. 2001. PMID: 11498460 Clinical Trial. - Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review. - Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Robinson JG. Robinson JG. Vasc Health Risk Manag. 2009;5(1):31-43. doi: 10.2147/vhrm.s3190. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436666 Free PMC article. Review.
Cited by
- Association between dietary intake of niacin and stroke in the US residents: evidence from national health and nutrition examination survey (NHANES) 1999-2018.
Qiu JY, Zhang WH, Zhu XM, Wu LD, Huang JH, Zhang J. Qiu JY, et al. Front Nutr. 2024 Jul 19;11:1391023. doi: 10.3389/fnut.2024.1391023. eCollection 2024. Front Nutr. 2024. PMID: 39101008 Free PMC article. - Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis.
Cheng Q, Sun J, Zhong H, Wang Z, Liu C, Zhou S, Deng J. Cheng Q, et al. Front Pharmacol. 2024 May 17;15:1393333. doi: 10.3389/fphar.2024.1393333. eCollection 2024. Front Pharmacol. 2024. PMID: 38828451 Free PMC article. - Role of Oxidative Stress in Sensorineural Hearing Loss.
Teraoka M, Hato N, Inufusa H, You F. Teraoka M, et al. Int J Mol Sci. 2024 Apr 9;25(8):4146. doi: 10.3390/ijms25084146. Int J Mol Sci. 2024. PMID: 38673731 Free PMC article. Review. - The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.
Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. Mhaimeed O, et al. Am J Prev Cardiol. 2024 Mar 18;18:100649. doi: 10.1016/j.ajpc.2024.100649. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38576462 Free PMC article. - Dyslipidemia: A Narrative Review on Pharmacotherapy.
de Oliveira LLH, de Assis ACR, Giraldez VZR, Scudeler TL, Soares PR. de Oliveira LLH, et al. Pharmaceuticals (Basel). 2024 Feb 23;17(3):289. doi: 10.3390/ph17030289. Pharmaceuticals (Basel). 2024. PMID: 38543075 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical